Literature DB >> 8915609

Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation.

A L Schwarzman1, D Goldgaber.   

Abstract

Aggregated amyloid beta-protein (A beta) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease. In contrast, in cerebrospinal fluid (CSF), A beta is found in a soluble form. The analysis of complexes of A beta with CSF proteins in a KBr gradient revealed an association of A beta only with free proteins and not with lipoprotein particles. Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation. In physiological buffers and CSF, TTR exclusively decreased the level of A beta pentamers. Endogenous TTR-A beta complexes were detected in human CSF by immunoprecipitation. Using site-directed mutagenesis and computer-assisted modelling, we identified amino acid residues on the surface of the TTR monomer that interact with A beta. Specific TTR immunoreactivity was detected in multiple cortical neurons and astrocytes in the human brain. We propose that A beta binding proteins play a key role in the modulation of A beta aggregation and normally prevent amyloid formation in biological fluids and in the brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915609     DOI: 10.1002/9780470514924.ch10

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  21 in total

1.  N-terminal region of myelin basic protein reduces fibrillar amyloid-β deposition in Tg-5xFAD mice.

Authors:  Ming-Hsuan Ou-Yang; Feng Xu; Mei-Chen Liao; Judianne Davis; John K Robinson; William E Van Nostrand
Journal:  Neurobiol Aging       Date:  2014-10-13       Impact factor: 4.673

2.  The systemic amyloid precursor transthyretin (TTR) behaves as a neuronal stress protein regulated by HSF1 in SH-SY5Y human neuroblastoma cells and APP23 Alzheimer's disease model mice.

Authors:  Xin Wang; Francesca Cattaneo; Lisa Ryno; John Hulleman; Natàlia Reixach; Joel N Buxbaum
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

3.  Inhibition of amyloid beta fibril formation by monomeric human transthyretin.

Authors:  Kanchan Garai; Ammon E Posey; Xinyi Li; Joel N Buxbaum; Rohit V Pappu
Journal:  Protein Sci       Date:  2018-03-14       Impact factor: 6.725

4.  Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy.

Authors:  James D Mills; Woojin S Kim; Glenda M Halliday; Michael Janitz
Journal:  Neurogenetics       Date:  2014-11-06       Impact factor: 2.660

5.  Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers.

Authors:  Jiali Du; Regina M Murphy
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

6.  Seasonal differences of gene expression profiles in song sparrow (Melospiza melodia) hypothalamus in relation to territorial aggression.

Authors:  Motoko Mukai; Kirstin Replogle; Jenny Drnevich; Gang Wang; Douglas Wacker; Mark Band; David F Clayton; John C Wingfield
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

Review 7.  Animal models of human amyloidoses: are transgenic mice worth the time and trouble?

Authors:  Joel N Buxbaum
Journal:  FEBS Lett       Date:  2009-07-20       Impact factor: 4.124

8.  Substrate specificity of transthyretin: identification of natural substrates in the nervous system.

Authors:  Márcia A Liz; Carolina E Fleming; Ana F Nunes; Maria R Almeida; Fernando M Mar; Youngchool Choe; Charles S Craik; James C Powers; Matthew Bogyo; Mónica M Sousa
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

Review 9.  Transthyretin: the servant of many masters.

Authors:  Joel N Buxbaum; Natàlia Reixach
Journal:  Cell Mol Life Sci       Date:  2009-07-31       Impact factor: 9.261

Review 10.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.